Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE PHOSPHATE vs TYLENOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.
Radical cure of relapsing malaria caused by Plasmodium vivax or P. ovale,Prevention of relapse in malaria due to P. vivax or P. ovale,Off-label: Terminal prophylaxis of malaria (after leaving endemic area) to prevent relapse,Combination therapy for treatment of uncomplicated malaria (with clindamycin or other agents)
Mild to moderate pain (FDA-approved),Fever (FDA-approved),Osteoarthritis pain (off-label),Patent ductus arteriosus in neonates (off-label IV formulation)
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Terminal elimination half-life is 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment
Primaquine is extensively metabolized in the liver, primarily via CYP2C8 and CYP2D6. Major metabolites include carboxyprimaquine and other oxidative products.
Primarily hepatic via conjugation with glucuronide (UGT1A1, UGT1A6, UGT1A9) and sulfate (SULT1A1, SULT1A3); minor oxidation by CYP2E1, CYP1A2, and CYP3A4 to N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Renal excretion of conjugated metabolites (glucuronide and sulfate conjugates) accounts for >90% of elimination; less than 5% excreted unchanged; minor biliary/fecal elimination (<5%)
Approximately 70% bound to plasma proteins (primarily albumin).
10-25% bound to plasma proteins (primarily albumin); binding is minimal and not clinically significant
2.5-3.5 L/kg; extensive distribution into tissues including liver, lungs, and erythrocytes.
0.8-1.0 L/kg; low Vd indicates limited extravascular distribution, consistent with limited CNS penetration
Oral: approximately 75-80% (first-pass metabolism reduces systemic availability; food decreases rate but not extent).
Oral: 60-90% (first-pass hepatic metabolism reduces bioavailability); Rectal: 70-90%; Intravenous: 100%
No specific guidelines; use with caution in renal impairment. For severe renal impairment (Cr Cl <30 m L/min), consider alternative therapy due to lack of data.
GFR 10-50 m L/min: Administer every 6 hours. GFR <10 m L/min: Administer every 8 hours.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor for adverse effects; dose adjustment not well defined, but consider reducing dose to 15 mg (base) daily and monitoring G6PD status.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%; maximum 2000 mg/day. Child-Pugh C: Reduce dose by 75%; maximum 1000 mg/day.
Children: For radical cure of P. vivax or P. ovale: 0.5 mg/kg (base) orally once daily for 14 days (maximum 30 mg). For prophylaxis: 0.5 mg/kg (base) orally once daily (maximum 30 mg) starting 1 day before travel, daily during travel, and 7 days after leaving endemic area. Must test for G6PD deficiency before use.
10-15 mg/kg orally every 4-6 hours; maximum 75 mg/kg/day or 5 doses per day.
No specific dose adjustments; use with caution due to age-related decline in hepatic and renal function. Monitor for hemolytic anemia and gastrointestinal effects. Consider lower starting dose (15 mg base daily) and adjust based on tolerability.
Reduce dose by 25-50% in frail elderly; maximum 3000 mg/day due to increased hepatotoxicity risk.
Primaquine phosphate can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency must be ruled out before starting treatment. Severe hemolysis may occur and can lead to death.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen in doses exceeding 4000 mg per day. The risk of acute liver failure may be higher in individuals with underlying liver disease and in those who consume alcohol chronically.
Hemolytic anemia in G6PD-deficient patients: Screen for G6PD deficiency prior to use and avoid in such patients unless benefit outweighs risk,Methemoglobinemia: Can occur, especially in patients with NADH-methemoglobin reductase deficiency or other predisposing conditions,Hematologic toxicity: Monitor blood counts; caution in patients with anemia or other blood disorders,Hepatic impairment: Use with caution; may need dose adjustment,Psychiatric effects: Rarely associated with anxiety, confusion, or psychosis
Hepatotoxicity: Risk increases with doses > 4000 mg/day, chronic alcohol use, or preexisting liver disease.,Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis.,Hypersensitivity: Rare anaphylaxis.
G6PD deficiency (absolute contraindication due to risk of hemolytic anemia),Known hypersensitivity to primaquine or other 8-aminoquinolines,Concurrent use with other hemolytic agents or drugs causing methemoglobinemia,Lupus erythematosus (relative contraindication; may exacerbate),Rheumatoid arthritis (relative contraindication; may exacerbate)
Hypersensitivity to acetaminophen,Severe hepatic impairment (e.g., active liver disease)
Grapefruit juice may increase plasma concentrations of primaquine, raising risk of toxicity. Take with food to reduce gastrointestinal irritation. No other significant food interactions known.
No significant food interactions. Alcohol consumption increases risk of hepatotoxicity; avoid concurrent use. High-carbohydrate meals may slightly delay absorption.
FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk of hemolytic anemia in G6PD-deficient fetuses; use only if clearly needed.
Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastroschisis and neural tube defects but confounding by indication is likely. Second and third trimesters: no consistent evidence of adverse fetal effects; chronic high doses may cause maternal hepatotoxicity with secondary fetal effects. Avoid prolonged high-dose therapy.
Excreted into breast milk in small amounts. M/P ratio not established. Use caution; avoid in G6PD-deficient infants. Consider risk of hemolytic anemia.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio approximately 0.9; peak milk concentration 10-15 µg/m L after 1g oral dose). Relative infant dose is <2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or drowsiness.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may affect efficacy; however, standard dosing is typically used with careful monitoring.
Increased clearance in pregnancy may reduce AUC by 25-30%; recommend standard dosing (500-1000mg every 4-6 hours, max 3000-4000mg/day). No dosage adjustment typically needed. Avoid extended-release formulations due to variable absorption.
Primaquine is the only 8-aminoquinoline used for radical cure of Plasmodium vivax and P. ovale hypnozoites. Screen for G6PD deficiency before initiation to prevent hemolytic anemia. Administer with food to reduce gastrointestinal upset. Watch for methemoglobinemia; discontinue if cyanosis or oxygen saturation drops. Avoid in pregnancy and lactation unless benefit outweighs risk.
Acetaminophen has minimal anti-inflammatory effect; prefer NSAIDs for inflammation. Max daily dose 3 g (or 2 g in at-risk patients). N-acetylcysteine is antidote for overdose; administer if serum level above nomogram line. Avoid in severe hepatic impairment. Intravenous formulation available for acute pain. Onset of action 30-60 min, duration 4-6 h. No effect on platelets or GI mucosa.
Take with food or milk to prevent stomach upset.,Complete the full course even if you feel better.,Report dark urine, yellowing of skin/eyes, or unusual tiredness immediately.,Avoid grapefruit juice as it may increase side effects.,Do not use during pregnancy or breastfeeding without consulting your doctor.,Keep out of reach of children and store at room temperature.
Do not exceed 3 g (3000 mg) per day from all products.,Check all over-the-counter medications for acetaminophen content.,Do not take with alcohol or if you have liver disease.,Seek immediate medical attention if overdose is suspected.,May be taken with food if GI upset occurs (though rare).
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE PHOSPHATE vs TYLENOL, answered by our medical review team.
PRIMAQUINE PHOSPHATE is a Antimalarial that works by Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.. TYLENOL is a Analgesic (non-opioid) that works by Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE PHOSPHATE and TYLENOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE PHOSPHATE is: Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.. The standard adult dose of TYLENOL is: 650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE PHOSPHATE and TYLENOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE PHOSPHATE is classified as Category D/X. FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk . TYLENOL is classified as Category C. Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.